The Lancet (British Edition), 398(10295), 143155
Clinical studies have shown Wegovy can help patients lose up to 15% of their body weight over approximately 68 weeks
The millennial-skewed telehealth platform Hims & Hers announced Monday that is now offering customers a compounded version of semaglutide, the active ingredient in popular weight loss drugs like Ozempic and Wegovy.
Providers typically recommend that patients choose a time they can reliably maintain, as missed doses or irregular administration can compromise glycemic control and weight management outcomes
These findings support future clinical trials to assess the efficacy of semaglutide in reducing the risk of kidney failure and cardiovascular complications in these patients. Journal reference: Apperloo, E.M., Gorriz, J.L., Soler, M.J